Welcome to our dedicated page for Biomerica news (Ticker: BMRA), a resource for investors and traders seeking the latest updates and insights on Biomerica stock.
Biomerica, Inc. (NASDAQ: BMRA) is a global biomedical technology company focused on advanced diagnostic and therapeutic products, with an emphasis on gastrointestinal and inflammatory diseases. The Biomerica news feed on Stock Titan highlights company announcements that explain how its diagnostic-guided therapies, rapid screening tests, and contract development and manufacturing (CDMO) services are evolving over time.
Readers can follow updates on the inFoods® IBS diagnostic-guided therapy, including clinical evidence, commercialization partnerships, and reimbursement milestones. Recent news has covered the American Medical Associations approval of a PLA code for inFoods IBS and the Centers for Medicare & Medicaid Services (CMS) decision to set a national Medicare payment rate for the test. Articles also describe the launch of the AI-backed inFoods IBS Trigger Food Navigator, a digital companion tool designed to support personalized IBS dietary therapy.
Biomerica news also covers regulatory authorizations and international expansion for its rapid screening portfolio. Examples include authorization by the Egyptian Drug Authority for the companys complete screening test portfolio and approvals by the United Arab Emirates Ministry of Health and Prevention for the Fortel® Ulcer and Fortel® Kidney tests for home use. These items provide insight into how Biomericas products are being introduced into new markets and care settings.
Investors and healthcare observers can also track updates on Biomericas expanding CDMO services, board and governance changes, and periodic financial results that discuss revenue mix, cost discipline, and the shift toward higher-margin diagnostic-guided therapy products and services. Bookmark this page to monitor BMRA news related to product launches, clinical publications, regulatory developments, commercial partnerships, and strategic initiatives as disclosed by the company.
Biomerica (Nasdaq: BMRA) announced that real-world clinical data on its inFoods® IBS diagnostic-guided therapy was accepted for poster presentation at Digestive Disease Week (DDW) 2026, May 2–5 in Chicago.
The poster, presented by investigators from Michigan Medicine and Cleveland Clinic, follows a June 2025 randomized trial in Gastroenterology; DDW embargoed data release begins 12:01 a.m. CDT on the presentation day.
Biomerica (NASDAQ: BMRA) announced that the Medicare Administrative Contractor confirmed inFoods® IBS claims can be reviewed on an individual, claim-by-claim basis, opening a Medicare billing pathway. The test has a dedicated PLA CPT code effective Oct 1, 2025 and a CMS national payment rate of $300 for dates of service on or after Jan 1, 2026.
The company and its CLIA-certified lab partner say properly documented claims with medical necessity and diagnosis codes are positioned for payment, supported by a Level 1 randomized trial published in Gastroenterology.
Biomerica (Nasdaq: BMRA) launched its inFoods® IBS platform in Canada on April 14, 2026, via exclusive distribution by Phoenix Airmid Biomedical and certified lab processing by CanAlt Health Labs.
The launch is the company’s first commercial entry into Canada, targeting an estimated ~18% prevalence (up to 5 million Canadians) and aims to expand access to a clinically validated, non‑pharmaceutical diagnostic‑guided therapy.
Biomerica (Nasdaq: BMRA) reported third quarter fiscal 2026 results for the period ended February 28, 2026, highlighting commercial progress and cost discipline. Key items: CMS set a $300 national Medicare payment rate for inFoods® IBS effective Jan 1, 2026; European revenue rose 45% in the quarter; R&D expenses fell 24% YTD.
Q3 net sales were $0.99M versus $1.12M a year earlier; Q3 net loss was $1.31M. Management cited transition to higher-margin diagnostics and CDMO services as drivers of future margin expansion.
Biomerica (Nasdaq: BMRA) received its first commercial order for Hp Detect™, a stool antigen test for Helicobacter pylori, from one of Europe’s largest clinical laboratory chains. The initial order targets the United Kingdom, where Hp Detect™ gained MHRA registration in February 2026.
Company says the account is a strategic reference customer with potential for recurring orders and wider EU distribution as Hp Detect™ is integrated into routine testing workflows, supported by NHS UK guidance recommending H. pylori testing for dyspepsia patients.
Biomerica (Nasdaq: BMRA) received MHRA registration on March 5, 2026 for its hp+detect™ diagnostic test, authorizing commercial sales in Great Britain.
The test detects Helicobacter pylori; the company is in active discussions with UK partners to access diagnostic labs and will provide updates as agreements are finalized.
Biomerica (Nasdaq: BMRA) reported real-world responder results for inFoods® IBS: 59.4% of 69 patients had ≥30% abdominal pain reduction and 68.1% had ≥30% bloating reduction using the FDA-recognized responder endpoint.
Mean pain scores fell 34.6% and bloating 41.7% at 8 weeks. Commercial milestones include a $300 national Medicare rate (effective Jan 1, 2026), a dedicated CPT PLA code (effective Oct 1, 2025), and a Henry Schein marketing services agreement.
Biomerica (Nasdaq: BMRA) announced that Vietnam’s Hanoi Department of Health approved EZ Detect™ for nationwide sales and distribution on Feb 18, 2026. The FDA-cleared, two-minute at-home colorectal screening test will be sold via a major distributor across pharmacies, hospitals, clinics, and online channels.
The approval targets Vietnam’s high unmet need: 16,835 new colorectal cancer cases in 2022 and a reported 45% five-year survival rate, versus 91% when detected early in the US.
Biomerica (Nasdaq: BMRA) reported Q2 fiscal 2026 results for the period ended November 30, 2025. Q2 revenue was $1.21M versus $1.64M year-ago and six-month revenue was $2.59M versus $3.44M prior year. Management highlighted a strategic pivot to higher-margin diagnostic-guided therapy products and cost discipline. Working capital improved 14.7% (about $457k) and cash increased to $2.5M. CMS later established a $300 Medicare payment rate for inFoods IBS effective January 1, 2026. Operating expenses declined year-to-date and R&D spending was reduced by 27% as the company reallocates resources to commercialization.
Biomerica (Nasdaq: BMRA) announced that CMS set a national Medicare payment rate of $300 for the inFoods® IBS test under the CLFS, effective for services paid with dates of service on or after January 1, 2026. The test secured a dedicated CPT® PLA code effective October 1, 2025. Medicare represents roughly 21% of US healthcare spending and Medicare-age adults are a meaningful share of IBS patients, supporting potential access expansion.
Clinical data from a randomized, multicenter trial showed 59.6% response for trigger-food elimination versus 42.2% control; subgroup results included 67.1% (IBS-C) and 66% (IBS-M) meeting FDA pain-reduction targets.